{"id":4867,"date":"2021-08-12T19:14:05","date_gmt":"2021-08-12T23:14:05","guid":{"rendered":"https:\/\/ccna-ccnv.ca\/ccna_publication\/preclinical-in-vivo-longitudinal-assessment-of-kg207-m-as-a-disease-modifying-alzheimers-disease-therapeutic-2\/"},"modified":"2024-12-03T14:57:53","modified_gmt":"2024-12-03T19:57:53","slug":"preclinical-in-vivo-longitudinal-assessment-of-kg207-m-as-a-disease-modifying-alzheimers-disease-therapeutic-2","status":"publish","type":"ccna_publication","link":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/preclinical-in-vivo-longitudinal-assessment-of-kg207-m-as-a-disease-modifying-alzheimers-disease-therapeutic-2\/","title":{"rendered":"Preclinical in vivo longitudinal assessment of KG207-M as a disease-modifying Alzheimer\u2019s disease therapeutic"},"content":{"rendered":"<h2 class=\"title\">Abstract<\/h2>\n<div id=\"enc-abstract\" class=\"abstract-content selected\">\n<p><i>In vivo<\/i>\u00a0biomarker abnormalities provide measures to monitor therapeutic interventions targeting amyloid-\u03b2 pathology as well as its effects on downstream processes associated with Alzheimer&rsquo;s disease pathophysiology. Here, we applied an\u00a0<i>in vivo<\/i>\u00a0longitudinal study design combined with imaging and cerebrospinal fluid biomarkers, mirroring those used in human clinical trials to assess the efficacy of a novel brain-penetrating anti-amyloid fusion protein treatment in the McGill-R-Thy1-APP transgenic rat model. The bi-functional fusion protein consisted of a blood-brain barrier crossing single domain antibody (FC5) fused to an amyloid-\u03b2 oligomer-binding peptide (ABP) via Fc fragment of mouse IgG (FC5-mFc2a-ABP). A five-week treatment with FC5-mFc2a-ABP (loading dose of 30 mg\/Kg\/iv followed by 15 mg\/Kg\/week\/iv for four weeks) substantially reduced brain amyloid-\u03b2 levels as measured by positron emission tomography and increased the cerebrospinal fluid amyloid-\u03b2<sub>42\/40<\/sub>\u00a0ratio. In addition, the 5-week treatment rectified the cerebrospinal fluid neurofilament light chain concentrations, resting-state functional connectivity, and hippocampal atrophy measured using magnetic resonance imaging. Finally, FC5-mFc2a-ABP (referred to as KG207-M) treatment did not induce amyloid-related imaging abnormalities such as microhemorrhage. Together, this study demonstrates the translational values of the designed preclinical studies for the assessment of novel therapies based on the clinical biomarkers providing tangible metrics for designing early-stage clinical trials.<\/p>\n<\/div>\n","protected":false},"author":19,"featured_media":0,"template":"","meta":{"_acf_changed":false},"studies-relation":[],"class_list":["post-4867","ccna_publication","type-ccna_publication","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Preclinical in vivo longitudinal assessment of KG207-M as a disease-modifying Alzheimer\u2019s disease therapeutic - CCNA - CCNV<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/preclinical-in-vivo-longitudinal-assessment-of-kg207-m-as-a-disease-modifying-alzheimers-disease-therapeutic-2\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Preclinical in vivo longitudinal assessment of KG207-M as a disease-modifying Alzheimer\u2019s disease therapeutic - CCNA - CCNV\" \/>\n<meta property=\"og:description\" content=\"Abstract In vivo\u00a0biomarker abnormalities provide measures to monitor therapeutic interventions ...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/preclinical-in-vivo-longitudinal-assessment-of-kg207-m-as-a-disease-modifying-alzheimers-disease-therapeutic-2\/\" \/>\n<meta property=\"og:site_name\" content=\"CCNA - CCNV\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-03T19:57:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/CCNA.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/preclinical-in-vivo-longitudinal-assessment-of-kg207-m-as-a-disease-modifying-alzheimers-disease-therapeutic-2\/\",\"url\":\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/preclinical-in-vivo-longitudinal-assessment-of-kg207-m-as-a-disease-modifying-alzheimers-disease-therapeutic-2\/\",\"name\":\"Preclinical in vivo longitudinal assessment of KG207-M as a disease-modifying Alzheimer\u2019s disease therapeutic - CCNA - CCNV\",\"isPartOf\":{\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#website\"},\"datePublished\":\"2021-08-12T23:14:05+00:00\",\"dateModified\":\"2024-12-03T19:57:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/preclinical-in-vivo-longitudinal-assessment-of-kg207-m-as-a-disease-modifying-alzheimers-disease-therapeutic-2\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/preclinical-in-vivo-longitudinal-assessment-of-kg207-m-as-a-disease-modifying-alzheimers-disease-therapeutic-2\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/preclinical-in-vivo-longitudinal-assessment-of-kg207-m-as-a-disease-modifying-alzheimers-disease-therapeutic-2\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ccna-ccnv.ca\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Preclinical in vivo longitudinal assessment of KG207-M as a disease-modifying Alzheimer\u2019s disease therapeutic\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#website\",\"url\":\"https:\/\/ccna-ccnv.ca\/fr\/\",\"name\":\"Canadian Consortium on Neurodegeneration in Aging\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#organization\"},\"alternateName\":\"CCNA - CCNV\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ccna-ccnv.ca\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#organization\",\"name\":\"Canadian Consortium on Neurodegeneration in Aging\",\"alternateName\":\"CCNA - CCNV\",\"url\":\"https:\/\/ccna-ccnv.ca\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/ccna-logo-on-white-background.jpg\",\"contentUrl\":\"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/ccna-logo-on-white-background.jpg\",\"width\":696,\"height\":696,\"caption\":\"Canadian Consortium on Neurodegeneration in Aging\"},\"image\":{\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Preclinical in vivo longitudinal assessment of KG207-M as a disease-modifying Alzheimer\u2019s disease therapeutic - CCNA - CCNV","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/preclinical-in-vivo-longitudinal-assessment-of-kg207-m-as-a-disease-modifying-alzheimers-disease-therapeutic-2\/","og_locale":"fr_CA","og_type":"article","og_title":"Preclinical in vivo longitudinal assessment of KG207-M as a disease-modifying Alzheimer\u2019s disease therapeutic - CCNA - CCNV","og_description":"Abstract In vivo\u00a0biomarker abnormalities provide measures to monitor therapeutic interventions ...","og_url":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/preclinical-in-vivo-longitudinal-assessment-of-kg207-m-as-a-disease-modifying-alzheimers-disease-therapeutic-2\/","og_site_name":"CCNA - CCNV","article_modified_time":"2024-12-03T19:57:53+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/CCNA.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Estimation du temps de lecture":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/preclinical-in-vivo-longitudinal-assessment-of-kg207-m-as-a-disease-modifying-alzheimers-disease-therapeutic-2\/","url":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/preclinical-in-vivo-longitudinal-assessment-of-kg207-m-as-a-disease-modifying-alzheimers-disease-therapeutic-2\/","name":"Preclinical in vivo longitudinal assessment of KG207-M as a disease-modifying Alzheimer\u2019s disease therapeutic - CCNA - CCNV","isPartOf":{"@id":"https:\/\/ccna-ccnv.ca\/fr\/#website"},"datePublished":"2021-08-12T23:14:05+00:00","dateModified":"2024-12-03T19:57:53+00:00","breadcrumb":{"@id":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/preclinical-in-vivo-longitudinal-assessment-of-kg207-m-as-a-disease-modifying-alzheimers-disease-therapeutic-2\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/preclinical-in-vivo-longitudinal-assessment-of-kg207-m-as-a-disease-modifying-alzheimers-disease-therapeutic-2\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/preclinical-in-vivo-longitudinal-assessment-of-kg207-m-as-a-disease-modifying-alzheimers-disease-therapeutic-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ccna-ccnv.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Preclinical in vivo longitudinal assessment of KG207-M as a disease-modifying Alzheimer\u2019s disease therapeutic"}]},{"@type":"WebSite","@id":"https:\/\/ccna-ccnv.ca\/fr\/#website","url":"https:\/\/ccna-ccnv.ca\/fr\/","name":"Canadian Consortium on Neurodegeneration in Aging","description":"","publisher":{"@id":"https:\/\/ccna-ccnv.ca\/fr\/#organization"},"alternateName":"CCNA - CCNV","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ccna-ccnv.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/ccna-ccnv.ca\/fr\/#organization","name":"Canadian Consortium on Neurodegeneration in Aging","alternateName":"CCNA - CCNV","url":"https:\/\/ccna-ccnv.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/ccna-ccnv.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/ccna-logo-on-white-background.jpg","contentUrl":"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/ccna-logo-on-white-background.jpg","width":696,"height":696,"caption":"Canadian Consortium on Neurodegeneration in Aging"},"image":{"@id":"https:\/\/ccna-ccnv.ca\/fr\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/ccna_publication\/4867","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/ccna_publication"}],"about":[{"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/types\/ccna_publication"}],"author":[{"embeddable":true,"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/users\/19"}],"wp:attachment":[{"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/media?parent=4867"}],"wp:term":[{"taxonomy":"studies-relation","embeddable":true,"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/studies-relation?post=4867"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}